NO992426L - N- (aryl / heteroaryl) amino acid derivatives, pharmaceutical compositions comprising the same, and methods for inhibiting <beta> -amyloid peptide release and / or its synthesis using such compounds - Google Patents

N- (aryl / heteroaryl) amino acid derivatives, pharmaceutical compositions comprising the same, and methods for inhibiting <beta> -amyloid peptide release and / or its synthesis using such compounds

Info

Publication number
NO992426L
NO992426L NO992426A NO992426A NO992426L NO 992426 L NO992426 L NO 992426L NO 992426 A NO992426 A NO 992426A NO 992426 A NO992426 A NO 992426A NO 992426 L NO992426 L NO 992426L
Authority
NO
Norway
Prior art keywords
synthesis
pharmaceutical compositions
compounds
amyloid peptide
methods
Prior art date
Application number
NO992426A
Other languages
Norwegian (no)
Other versions
NO992426D0 (en
Inventor
James E Audia
Beverly K Folmer
Varghese John
Lee H Latimer
Jeffrey S Nissen
Warren J Porter
Eugene D Thorsett
Jing Wu
Original Assignee
Elan Pharm Inc
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc, Lilly Co Eli filed Critical Elan Pharm Inc
Publication of NO992426D0 publication Critical patent/NO992426D0/en
Publication of NO992426L publication Critical patent/NO992426L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Det er omtalt forbindelser som inhiberer 13-amyloidpeptidfrigivning og/eller dets syntese, og følgelig kan anvendes for å behandle Alzheimers sykdom. Også omtalt er farmasøytiske sammensetninger som omfatter en forbindelse som inhiberer 15- amyloidpeptidfrigivning og/eller dets syntese så vel som fremgangsmåter for å behandle Alzheimers sykdom både profylaktisk og terapeutisk med slike farmasøytiske sammensetningerCompounds that inhibit 13-amyloid peptide release and / or its synthesis are disclosed and can therefore be used to treat Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits 15-amyloid peptide release and / or its synthesis as well as methods of treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

NO992426A 1996-11-22 1999-05-20 N- (aryl / heteroaryl) amino acid derivatives, pharmaceutical compositions comprising the same, and methods for inhibiting <beta> -amyloid peptide release and / or its synthesis using such compounds NO992426L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75533496A 1996-11-22 1996-11-22
PCT/US1997/018704 WO1998022493A2 (en) 1996-11-22 1997-11-20 N-(ARYL/HETEROARYL) AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS

Publications (2)

Publication Number Publication Date
NO992426D0 NO992426D0 (en) 1999-05-20
NO992426L true NO992426L (en) 1999-06-30

Family

ID=25038718

Family Applications (1)

Application Number Title Priority Date Filing Date
NO992426A NO992426L (en) 1996-11-22 1999-05-20 N- (aryl / heteroaryl) amino acid derivatives, pharmaceutical compositions comprising the same, and methods for inhibiting <beta> -amyloid peptide release and / or its synthesis using such compounds

Country Status (13)

Country Link
EP (1) EP0942923A2 (en)
JP (1) JP2001519769A (en)
CN (1) CN1237978A (en)
AU (1) AU5354398A (en)
BR (1) BR9714358A (en)
CA (1) CA2270876A1 (en)
HU (1) HUP0001383A3 (en)
ID (1) ID22275A (en)
IL (1) IL129477A0 (en)
NO (1) NO992426L (en)
NZ (1) NZ335157A (en)
TR (1) TR199901132T2 (en)
WO (1) WO1998022493A2 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP990246A2 (en) 1998-08-07 2000-06-30 Du Pont Pharm Co Succinoylamino benzodiazepines as inhibitors of a beta protein production
NZ525513A (en) 1998-08-07 2004-09-24 Pont Pharmaceuticals Du Succinoylamino lactams as inhibitors of Abeta protein production
US6486350B1 (en) 1998-09-30 2002-11-26 Elan Pharmaceuticals Inc. Biological reagents and methods for determining the mechanism in the generation of β-amyloid peptide
US6737038B1 (en) 1998-11-12 2004-05-18 Bristol-Myers Squibb Company Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
EP1313426A2 (en) 1998-12-24 2003-05-28 Bristol-Myers Squibb Pharma Company Succinoylamino benzodiazepines as inhibitors of a-beta protein production
US6960576B2 (en) 1999-09-13 2005-11-01 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production
US6503902B2 (en) 1999-09-13 2003-01-07 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of a β protein production
WO2001027091A1 (en) 1999-10-08 2001-04-19 Du Pont Pharmaceuticals Company AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
US6525044B2 (en) 2000-02-17 2003-02-25 Bristol-Myers Squibb Company Succinoylamino carbocycles and heterocycles as inhibitors of a-β protein production
BR0107532A (en) 2000-04-03 2004-11-03 Bristol Myers Squibb Pharma Co Compound, use of compound, method for treating neurological dysfunctions associated with b-amyloid production, method of inhibiting y-secretase activity and pharmaceutical composition
CA2403550A1 (en) 2000-04-03 2001-10-11 Hong Liu Cyclic lactams as inhibitors of a-.beta. protein production
US6632812B2 (en) 2000-04-11 2003-10-14 Dupont Pharmaceuticals Company Substituted lactams as inhibitors of Aβ protein production
WO2001087354A2 (en) 2000-05-17 2001-11-22 Bristol-Myers Squibb Pharma Company Use of small molecule radioligands for diagnostic imaging
BR0106717A (en) 2000-06-01 2002-04-16 Bristol Myers Squibb Pharma Co Compounds, pharmaceutical composition and uses of innovative lactam compounds
US6432944B1 (en) 2000-07-06 2002-08-13 Bristol-Myers Squibb Company Benzodiazepinone β-amyloid inhibitors: arylacetamidoalanyl derivatives
ES2536449T3 (en) 2000-08-24 2015-05-25 University Of Pittsburgh Of The Commonwealth System Of Higher Education Thioflavin derivatives for use in the diagnosis of Alzheimer's disease
US7270800B2 (en) 2000-08-24 2007-09-18 University Of Pittsburgh Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
US6657070B2 (en) 2000-12-13 2003-12-02 Wyeth Production of chirally pure α-amino acids and N-sulfonyl α-amino acids
KR100869061B1 (en) 2000-12-13 2008-11-17 와이어쓰 Heterocyclic sulfonamide inhibitors of beta amyloid production
CH698246B1 (en) * 2001-12-20 2009-06-30 Hoffmann La Roche Test to identify inhibitors of beta secretases.
DE10306202A1 (en) 2003-02-13 2004-08-26 Grünenthal GmbH 2-(hetero)aryl-2-(N-((hetero)aryl)-amino)-acetic acid derivatives useful e.g. for treating anxiety, inflammation, allergy, depression, diarrhea or especially pain is NMDA antagonist
CN102532055B (en) * 2003-03-14 2016-05-11 匹兹堡大学联邦制高等教育 Benzothiazole derivative compounds, composition and purposes
CL2004000647A1 (en) 2003-03-31 2005-02-04 Wyeth Corp COMPOUNDS DERIVED FROM SULFONAMIDE HETEROCICLES CONTAINING FLUORO AND TRIFLUORO RENT; PHARMACEUTICAL COMPOSITION; PHARMACEUTICAL KIT; PREPARATION PROCEDURE; AND ITS USE AS BETA AMILOID INHIBITORS TO TREAT ALZHEIMER, ANGIOPATIA AM
EP1633350B1 (en) 2003-06-05 2012-10-03 Elan Pharmaceuticals, Inc. Acylated amino acid amidyl pyrazoles and related compounds
US8236282B2 (en) 2003-08-22 2012-08-07 University of Pittsburgh—of the Commonwealth System of Higher Education Benzothiazole derivative compounds, compositions and uses
ATE443701T1 (en) 2004-01-16 2009-10-15 Wyeth Corp HETEROCYCLIC AZOLE-CONTAINING SULFONAMIDINE INHIBITORS OF BETA-AMYLOID PRODUCTION
EP1725522B1 (en) 2004-03-03 2014-09-10 GlaxoSmithKline LLC Aniline derivatives as selective androgen receptor modulators
EP1871379A4 (en) * 2005-04-15 2010-06-02 Glaxosmithkline Llc Cyanoarylamines
CN100999546B (en) * 2007-01-11 2010-08-11 清华大学 Polypeptide compound with aza-containing heterocyclic modification and its application
WO2012172449A1 (en) 2011-06-13 2012-12-20 Pfizer Inc. Lactams as beta secretase inhibitors
CN111777571B (en) * 2020-06-28 2023-07-11 武汉药明康德新药开发有限公司 Synthesis method of chiral 2-amino-3- (1, 3-benzothiazole-2-yl) propionic acid hydrochloride

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT721449E (en) * 1993-10-01 2002-06-28 Merrell Pharma Inc BETA-AMYLOID PROTEIN PRODUCTION INHIBITORS
US6017887A (en) * 1995-01-06 2000-01-25 Sibia Neurosciences, Inc. Peptide, peptide analog and amino acid analog protease inhibitors

Also Published As

Publication number Publication date
IL129477A0 (en) 2000-02-29
EP0942923A2 (en) 1999-09-22
NO992426D0 (en) 1999-05-20
JP2001519769A (en) 2001-10-23
WO1998022493A2 (en) 1998-05-28
AU5354398A (en) 1998-06-10
HUP0001383A1 (en) 2001-05-28
CN1237978A (en) 1999-12-08
NZ335157A (en) 2001-01-26
BR9714358A (en) 2000-03-21
TR199901132T2 (en) 1999-08-23
HUP0001383A3 (en) 2001-11-28
WO1998022493A3 (en) 1998-07-23
ID22275A (en) 1999-09-23
CA2270876A1 (en) 1998-05-28

Similar Documents

Publication Publication Date Title
NO992426L (en) N- (aryl / heteroaryl) amino acid derivatives, pharmaceutical compositions comprising the same, and methods for inhibiting &lt;beta&gt; -amyloid peptide release and / or its synthesis using such compounds
NO992463L (en) N- (aryl / heteroarylacetyl) amino acid esters, pharmaceutical compositions including the same, and methods for inhibiting &lt;beta&gt; -amyloid peptide release and / or its synthesis using such compounds
NO992368L (en) Methods and Compounds for Inhibiting &lt;beta&gt; -amyloid Release and / or its Synthesis
NO994016L (en) Heterocyclic Compounds and Their Use for Inhibition of &lt;beta&gt; Amyloid Peptide
CA2367017A1 (en) Inhibitors of impdh enzyme
BR0212787A (en) Pharmaceutically acceptable compound or salt thereof, methods of treating or preventing disease and preparing a compound, use of a compound or salt, and pharmaceutical composition
BR0213139A (en) Compound, method of treating or preventing disease and preparing a compound, use of a compound and pharmaceutical composition
BR0314071A (en) 1,3-Diamino-2-hydroxypropane prodrug derivatives
BR0211119A (en) Compound, method of treating a patient who has, or preventing a patient from catching, a disease or condition, use of a compound, and method for making a compound
BRPI0409624A (en) Benzamide 2-hydroxy-3-diaminoalkanes
BR0211122A (en) Compound, methods for treating or preventing disease and for making a compound, intermediate, and use of a compound or salt
BR9814643A (en) Aromatic hydroxamic acid sulfone metalloprotease inhibitor
NO20003018D0 (en) Triazinangiogenese inhibitors
BR0210391A (en) Compound, methods of treating a patient who has or prevent a patient from contracting a disease or condition and preparing a compound, and, using a compound
DK0468012T3 (en) 17beta-substituted 4-aza-5alpha-androstan-3-one derivatives and process for their preparation
NO991494L (en) &lt;beta&gt; -sulfonylhydroxamic acids as matrix metalloproteinase inhibitors
BR0211118A (en) Compound, methods for treating or preventing disease and for making a compound, intermediate, and use of a compound or salt
NO20000231L (en) Dolastatin-15 derivatives
BR0316629A (en) Substituted urea and carbamates
HUP0102255A2 (en) Vla-4 inhibitor omepupa-v, pharmaceutical compositions comprising thereof and their use
WO1998022441A3 (en) N-(aryl/heteroaryl) amino acid esters, pharmaceutical compositions, and methods for inhibiting beta-amyloid peptide and/or its synthesis
CA2266759A1 (en) 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
BR0314180A (en) Substituted Aminoethers for the Treatment of Alzheimer&#39;s Disease
BR0211121A (en) Compound, methods for treating or preventing disease and for making a compound, intermediate, and use of a compound or salt
WO2004029019A8 (en) Compounds for the treatment of alzheimer’s disease

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application